Besides combining afatinib with standard chemotherapy and/or radiotherapy, combinations with other targeted agents such as CDK and Akt inhibitors have shown synergistic effects in HNSCC cell lines (Beck et al., 2016; Silva‐Oliveira et al., 2017). The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.